Our top pick for
Unity Biotechnology, Inc is a biotechnology business based in the US. Unity Biotechnology shares (UBX) are listed on the NASDAQ and all prices are listed in US Dollars. Unity Biotechnology employs 76 staff and has a market cap (total outstanding shares value) of USD$369.3 million.
|52-week range||USD$2.72 - USD$12.46|
|50-day moving average||USD$6.9656|
|200-day moving average||USD$5.254|
|Wall St. target price||USD$5.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.973|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-70,957,000|
|Return on assets TTM||-37.95%|
|Return on equity TTM||-86.73%|
|Market capitalisation||USD$369.3 million|
TTM: trailing 12 months
There are currently 2.8 million Unity Biotechnology shares held short by investors – that's known as Unity Biotechnology's "short interest". This figure is 9% down from 3.0 million last month.
There are a few different ways that this level of interest in shorting Unity Biotechnology shares can be evaluated.
Unity Biotechnology's "short interest ratio" (SIR) is the quantity of Unity Biotechnology shares currently shorted divided by the average quantity of Unity Biotechnology shares traded daily (recently around 897912.62135922). Unity Biotechnology's SIR currently stands at 3.09. In other words for every 100,000 Unity Biotechnology shares traded daily on the market, roughly 3090 shares are currently held short.
However Unity Biotechnology's short interest can also be evaluated against the total number of Unity Biotechnology shares, or, against the total number of tradable Unity Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Unity Biotechnology's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Unity Biotechnology shares in existence, roughly 50 shares are currently held short) or 0.0762% of the tradable shares (for every 100,000 tradable Unity Biotechnology shares, roughly 76 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Unity Biotechnology.
Find out more about how you can short Unity Biotechnology stock.
We're not expecting Unity Biotechnology to pay a dividend over the next 12 months.
Over the last 12 months, Unity Biotechnology's shares have ranged in value from as little as $2.72 up to $12.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Unity Biotechnology's is 0.3144. This would suggest that Unity Biotechnology's shares are less volatile than average (for this exchange).
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and neurological disorders, as well as kidney and liver diseases. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in South San Francisco, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.